July 9, 2020 / 11:09 AM / a month ago

BRIEF-Bayer's Finerenone Meets Primary Endpoint In Phase III FIDELIO-DKD Renal Outcomes Study

July 9 (Reuters) - BAYER AG:

* BAYER’S FINERENONE MEETS PRIMARY ENDPOINT IN PHASE III FIDELIO-DKD RENAL OUTCOMES STUDY IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES

* THE RESULTS SHOW THAT THE INVESTIGATIONAL DRUG FINERENONE DELAYED THE PROGRESSION OF CKD BY SIGNIFICANTLY REDUCING THE COMBINED RISK OF TIME TO FIRST OCCURRENCE OF KIDNEY FAILURE, A SUSTAINED DECREASE OF ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) GREATER THAN OR EQUAL TO 40% FROM BASELINE OVER A PERIOD OF AT LEAST FOUR WEEKS, OR RENAL DEATH

* CLINICAL DATA FROM FIDELIO-DKD WILL BE PRESENTED AT AN UPCOMING SCIENTIFIC MEETING

* WILL DISCUSS THE DATA WITH HEALTH AUTHORITIES REGARDING THE SUBMISSION OF MARKETING AUTHORIZATION APPLICATION Source text: bit.ly/2ANHUhi Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below